))
Market Access and Valuation: Key Considerations for Multi-Indication Products
Manage episode 502638148 series 3685050
Content provided by Demy-Colton. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Demy-Colton or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Join us for an episode featuring a distinguished panel of experts as they dive into pricing and deal valuation dynamics for multi-indication products. The conversation explores the key questions commercialization partners, acquirers, and capital providers ask when evaluating both multi-indication and platform products for deal valuation.
Hear firsthand insights from CEOs, business development executives, market access leaders, country managers, and royalty investors representing leading companies such as Alexion, DRI Capital, Genentech, Genzyme, GSK, and Pfizer.
24 episodes
Share
